AAA President Takes Novartis Oncology Top Job, As Barrett Leaves For Biotech
Liz Barrett leaves her fresh role as head of Novartis Oncology, leaving AAA President Susanne Schaffert to fill the gap.
You may also be interested in...
Tschudin talked to Scrip about taking over as Novartis Pharmaceuticals president, why inclisiran is different from marketed PCSK9 inhibitors and prioritizing investment behind multiple new launches.
In an interview at Novartis' research campus in Cambridge, Mass., Schaffert spoke about the upcoming launch of Piqray for breast cancer, building in radiopharmaceuticals, Kymriah's ongoing manufacturing challenges and more.
The former Novartis Oncology CEO will oversee the FDA approval and launch of UroGen's lead asset, UGN-101, for low-grade upper tract urothelial cancer, and build out the company's longer-term strategy. Scrip talked to Barrett about the transition from big pharma leadership to the CEO of a small biopharma.